CClinicalTrials.gg
CompletedNCT03306537Updated Mar 20, 2019

Sensor Validation Study - Quality Assurance

An observational study in Respiratory Rate, sponsored by PMD Solutions. Completed at 1 site in United Kingdom. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2019-03-20.

Sponsored by PMD Solutions · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
34
Ages
Up to 18 Years
Sex
All
01

Study summary

The respiratory rate is an important parameter in clinical medicine. It is defined as the number of breaths per minute. Currently this is measured at the bedside in clinical practice by counting the breaths, however the gold standard for measuring this vital sign is the capnograph. For the patient, this involves wearing a tube in their nose and around their ears while trying to minimise their movement and talking so that the measurements can be taken.

A new respiratory rate monitor, RespiraSense, is non-invasive and measures the respiratory rate by measuring the displacement between the ribs and abdomen. This research study is intended to validate that this technology is effective and accurate on people with a bigger body mass.

Subjects with a BMI > 35 will be invited to participate should they meet all of the eligibility criteria. If patients agree to participate, following informed consent, subjects will be monitored for one hour with both the capnograph and RespiraSense measuring at the same time so their results can be compared

02

Conditions studied

  • Respiratory Rate
03

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Obese patients with a BMI ≥35

Inclusion criteria

  • ≥ 18 Years
  • Have a BMI ≥35

    • For the sub-group analysis at least 5 subjects with a BMI 35-49 and at least 5 BMI > 50 will be needed
  • Are willing to voluntarily sign a statement of informed consent to participate in this investigation

Exclusion criteria

Exclusion Criteria:

  • Allergic to medical grade skin adhesive
  • Continuous oral long term steroid use. To be free from oral steroid use this is defined as not using oral steroids in the 4 weeks previous to enrolment
  • Patients under the influence of substance abuse (drug or alcohol) that may interfere with their ability to cooperate and comply with the investigation procedures
  • Any disorder, including cognitive dysfunction, which would affect the ability to accurately complete questionnaires and freely give full informed consent
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
34 participants (actual)
Patient registry
No

Interventions

  • DeviceRespiraSense Respiratory Rate Monitor

    RespiraSense device will be attached at the same time as the capnograph (gold standard) and both will measure simultaneously for one hour

05

What researchers measure

Primary outcomes

  1. Comparison of PMD RespiraSense against capnography in obese patients.

    Analysed using a Bland Altman (BA) analysis to measure limits of agreement between both methods. The BA analysis will correct for repeated measures within each subject if required. In addition, a Deming Regression will be performed on the collected data.

    Time frame: 1 hour

Secondary outcomes

  1. Comparison of PMD RespiraSense in obese patients with BMI below 50 and those with BMI of 50 or above.

    Analysed using a Bland Altman (BA) analysis to measure limits of agreement between both methods. The BA analysis will correct for repeated measures within each subject if required. In addition, a Deming Regression will be performed on the collected data.

    Time frame: 1 hour

  2. Identification of any accuracy spread patterns as BMI increases.

    Analysed using a Bland Altman (BA) analysis to measure limits of agreement between both methods. The BA analysis will correct for repeated measures within each subject if required. In addition, a Deming Regression will be performed on the collected data.

    Time frame: 1 hour

  3. Collection of feedback on device comfort when worn by patients with high BMI.

    Will not be analysed formally.

    Time frame: 1 hour

Other outcomes

  1. Exploratory: To measure RespiraSense device alarm generation and assess the rationale behind these to determine if false alarms and therefore alarm fatigue is occurring

    Will not be analysed formally.

    Time frame: 1 hour

06

Study locations

1 site
  • Queen Alexandra Hospital
    Portsmouth, PO6 3LY, United Kingdom
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03306537
Lead sponsor
PMD Solutions
Responsible party
Sponsor
First posted
Oct 11, 2017
Start date
Jul 28, 2017
Primary completion
Aug 7, 2018
Completion
Sep 7, 2018
Last update
Mar 20, 2019

Study contacts

Lorraine Albon
principal investigator · Portsmouth Hospitals NHS Trust

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion